Literature DB >> 22389040

2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Bhaskar Dasgupta1, Marco A Cimmino, Hilal Maradit Kremers, Wolfgang A Schmidt, Michael Schirmer, Carlo Salvarani, Artur Bachta, Christian Dejaco, Christina Duftner, Hanne Slott Jensen, Pierre Duhaut, Gyula Poór, Novák Pál Kaposi, Peter Mandl, Peter V Balint, Zsuzsa Schmidt, Annamaria Iagnocco, Carlotta Nannini, Fabrizio Cantini, Pierluigi Macchioni, Nicolò Pipitone, Montserrat Del Amo, Georgina Espígol-Frigolé, Maria C Cid, Víctor M Martínez-Taboada, Elisabeth Nordborg, Haner Direskeneli, Sibel Zehra Aydin, Khalid Ahmed, Brian Hazleman, Barbara Silverman, Colin Pease, Richard J Wakefield, Raashid Luqmani, Andy Abril, Clement J Michet, Ralph Marcus, Neil J Gonter, Mehrdad Maz, Rickey E Carter, Cynthia S Crowson, Eric L Matteson.   

Abstract

The objective of this study was to develop European League Against Rheumatism/American College of Rheumatology classification criteria for polymyalgia rheumatica (PMR). Candidate criteria were evaluated in a 6-month prospective cohort study of 125 patients with new-onset PMR and 169 non-PMR comparison subjects with conditions mimicking PMR. A scoring algorithm was developed based on morning stiffness >45 minutes (2 points), hip pain/limited range of motion (1 point), absence of rheumatoid factor and/or anti-citrullinated protein antibody (2 points), and absence of peripheral joint pain (1 point). A score ≥4 had 68% sensitivity and 78% specificity for discriminating all comparison subjects from PMR. The specificity was higher (88%) for discriminating shoulder conditions from PMR and lower (65%) for discriminating RA from PMR. Adding ultrasound, a score ≥5 had increased sensitivity to 66% and specificity to 81%. According to these provisional classification criteria, patients ≥50 years old presenting with bilateral shoulder pain, not better explained by an alternative pathology, can be classified as having PMR in the presence of morning stiffness >45 minutes, elevated C-reactive protein and/or erythrocyte sedimentation rate, and new hip pain. These criteria are not meant for diagnostic purposes.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 22389040     DOI: 10.1002/art.34356

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  70 in total

1.  Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.

Authors:  Izzat Shbeeb; Divya Challah; Shafay Raheel; Cynthia S Crowson; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

2.  Polymyalgia rheumatica following paraspinal muscle inflammation and sacroiliitis.

Authors:  Taeseok Lim; Seokyung Woo; Yoon Gwon Mun; Eunjung Yim; Jung Hee Koh; Kyung-Su Park
Journal:  Korean J Intern Med       Date:  2015-04-29       Impact factor: 2.884

3.  [Recommendations of the Austrian Society of Rheumatology/Austrian Radiology-Rheumatology Initiative for Musculoskeletal Ultrasound for the application of ultrasound in rheumatology].

Authors:  Christina Duftner; Christian Dejaco; Franz Kainberger; Klaus Machold; Peter Mandl; Thomas Nothnagl; Tobias DeZordo; Rusmir Husic; Claudia Schüller-Weidekamm; Michael Schirmer
Journal:  Wien Klin Wochenschr       Date:  2014-10-02       Impact factor: 1.704

Review 4.  [Diagnostics and treatment of polymyalgia rheumatica].

Authors:  C Dejaco; E L Matteson; F Buttgereit
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

Review 5.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

6.  [Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)].

Authors:  J C Henes; H Schulze-Koops; M Witt; H P Tony; F Mueller; M Grunke; M Czihal; T Dörner; F Proft
Journal:  Z Rheumatol       Date:  2018-02       Impact factor: 1.372

7.  Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.

Authors:  Lindsay Lally; Lindsy Forbess; Christopher Hatzis; Robert Spiera
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

8.  Monoclonal gammopathy in rheumatic diseases.

Authors:  Yue Yang; Long Chen; Yuan Jia; Yang Liu; Lei Wen; Yaoxian Liang; Yuan An; Shi Chen; Yin Su; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2018-03-13       Impact factor: 2.980

Review 9.  Clinical practice. Giant-cell arteritis and polymyalgia rheumatica.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  N Engl J Med       Date:  2014-07-03       Impact factor: 91.245

Review 10.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.